|
|
 |
|
Viewing report
|
|
|
|
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Leukemias and Lymphomas
Bioseeker, June 2007, Pages: 430
In this triple analysis report the author has analyzed three major and intertwined areas of cancer R&D, Antibody drug target, Leukemias and Lymphomas, which are all subjects to an extensive number of innovative drug candidates. This extensive 430+ pages report compiles and analyzes in parallel the progress concerning drug development and competitive situation in Antibody drug targeting and further give an in depth analysis in two key oncology areas; Leukemia and Lymphoma. The report will not only provide a framework but also a careful identification and evaluation of drug candidates, technologies and competitors.
There are currently more than 400 antibody based drugs in development for the treatment of cancer. The author has surveyed these antibodies and identified 132 antibody drug targets, belonging to 220 antibody drugs. In all they range from preclinical development to established therapy leaders in the market place. In total more than 420 clinical trials are included in this analysis, covering more than 30 different cancer indications plus diagnosis and supportive care.
Drug targets and their associated antibodies have been analyzed by the author according to:
- 34 Different molecular functions of target
- 13 Major signaling pathways
- Cancer stem cells
- Conjugated antibodies
- Therapeutic effects: Anti-angiogenesis, Apoptosis and Protein Kinase Inhibition
- 31 Targeted cancer indications
- Availability of expression profiles of targets in human tissues, cancer tissues, established cell lines and primary cell cultures
- Antibody therapeutic companies
Customers who bought this item also bought
Antibody Drug Targets and Special Focus on Leukemias & Lymphomas
Triple Analysis: Decoding Big Pharma's R&D Strategy in Oncology and Special Focus on Leukemias and Lymphomas
U.S. Monoclonal Antibody Cancer Therapeutics Market
GPC Biotech AG - Financial and Strategic Analysis Review
The Commercial Success of Cancer Therapeutic Antibodies - The Formation of a Second Wave
Analytical Tool - Hematological Cancers
Triple Progress Analysis: Lymphoma Therapeutics, Protein Kinase Inhibitors & Therapeutic Antibodies
Hematological Cancers - A Therapeutic & Competitive Insight
Hematological Malignancies: Companies Target Niche Indications to Facilitate Market Entry
Personalized Medicine - Scientific and Commercial Aspects
Top 7 Cancer Indications - Therapeutic & Competitive Insights
|
|
|
|
